Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month. They could also have a chilling effect across the industry. 

Just before Labor Day, Novartis reported that its cardiac therapy, pelacarsen, failed in a widely watched, seven-year clinical trial. The drug was designed to reduce the rates of heart attack or stroke by lowering lipoprotein a, or Lp(a), a type of lipid that, at elevated concentrations, increases the likelihood of severe heart problems. An estimated 20% of people have abnormally high levels. 

Novartis’ drug was the first stab at a new type of cardiovascular treatment, which multiple other drug companies are also pursuing, investing billions of dollars in their own Lp(a) medications. 

STAT+ Exclusive Story

STAT+



This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe